Top

Published in:

Open Access 01-12-2023 | Hepatocellular Carcinoma | Review

Dysregulated cholesterol regulatory genes in hepatocellular carcinoma

Authors: Dan Cao, Huan Liu

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Cholesterol is an indispensable component in mammalian cells, and cholesterol metabolism performs important roles in various biological activities. In addition to the Warburg effect, dysregulated cholesterol metabolism is one of the metabolic hallmarks of several cancers. It has reported that reprogrammed cholesterol metabolism facilitates carcinogenesis, metastasis, and drug-resistant in various tumors, including hepatocellular carcinoma (HCC). Some literatures have reported that increased cholesterol level leads to lipotoxicity, inflammation, and fibrosis, ultimately promoting the development and progression of HCC. Contrarily, other clinical investigations have demonstrated a link between higher cholesterol level and lower risk of HCC. These incongruent findings suggest that the connection between cholesterol and HCC is much complicated. In this report, we summarize the roles of key cholesterol regulatory genes including cholesterol biosynthesis, uptake, efflux, trafficking and esterification in HCC. In addition, we discuss promising related therapeutic targets for HCC.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef

Luo J, Yang H, Song B-L. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21:225–45.PubMedCrossRef

Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1:31–9.PubMedCrossRef

Javitt NB. Bile acid synthesis from cholesterol: regulatory and auxiliary pathways. FASEB J. 1994;8:1308–11.PubMedCrossRef

Göbel A, Rauner M, Hofbauer LC, Rachner TD. Cholesterol and beyond: the role of the mevalonate pathway in cancer biology. Biochim Biophys Acta Rev Cancer. 2020;1873: 188351.PubMedCrossRef

Xu H, Zhou S, Tang Q, Xia H, Bi F. Cholesterol metabolism: new functions and therapeutic approaches in cancer. Biochim Biophys Acta Rev Cancer. 2020;1874: 188394.PubMedCrossRef

Bhattacharjee P, Rutland N, Iyer MR. Targeting sterol O-acyltransferase/Acyl-CoA: cholesterol acyltransferase (ACAT): a perspective on small-molecule inhibitors and their therapeutic potential. J Med Chem. 2022;65:16062–98.PubMedCrossRef

Wang L-J, Song B-L. Niemann-Pick C1-like 1 and cholesterol uptake. Biochim Biophys Acta. 2012;1821:964–72.PubMedCrossRef

Kober DL, Xu S, Li S, Bajaj B, Liang G, Rosenbaum DM, et al. Identification of a degradation signal at the carboxy terminus of SREBP2: a new role for this domain in cholesterol homeostasis. Proc Natl Acad Sci USA. 2020;117:28080–91.PubMedPubMedCentralCrossRef

10.

Kuzu OF, Gowda R, Noory MA, Robertson GP. Modulating cancer cell survival by targeting intracellular cholesterol transport. Br J Cancer. 2017;117:513–24.PubMedPubMedCentralCrossRef

11.

He J, Siu MKY, Ngan HYS, Chan KKL. Aberrant cholesterol metabolism in ovarian cancer: identification of novel therapeutic targets. Front Oncol. 2021;11: 738177.PubMedPubMedCentralCrossRef

12.

Alannan M, Trézéguet V, Amoêdo ND, Rossignol R, Mahfouf W, Rezvani HR, et al. Rewiring lipid metabolism by targeting PCSK9 and HMGCR to treat liver cancer. Cancers. 2022;15:3.PubMedPubMedCentralCrossRef

13.

Liang B, Chen R, Song S, Wang H, Sun G, Yang H, et al. ASPP2 inhibits tumor growth by repressing the mevalonate pathway in hepatocellular carcinoma. Cell Death Dis. 2019;10:830.PubMedPubMedCentralCrossRef

14.

Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, et al. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Can Res. 2011;71:2286–97.CrossRef

15.

Dong L, Xue L, Zhang C, Li H, Cai Z, Guo R. HSP90 interacts with HMGCR and promotes the progression of hepatocellular carcinoma. Mol Med Rep. 2018;19:524–32.PubMed

16.

Ogura S, Yoshida Y, Kurahashi T, Egawa M, Furuta K, Kiso S, et al. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma. Oncotarget. 2018;9:21022–35.PubMedPubMedCentralCrossRef

17.

Cheng J, Ohsaki Y, Tauchi-Sato K, Fujita A, Fujimoto T. Cholesterol depletion induces autophagy. Biochem Biophys Res Commun. 2006;351:246–52.PubMedCrossRef

18.

Cirmena G, Franceschelli P, Isnaldi E, Ferrando L, De Mariano M, Ballestrero A, et al. Squalene epoxidase as a promising metabolic target in cancer treatment. Cancer Lett. 2018;425:13–20.PubMedCrossRef

19.

Liu D, Wong CC, Fu L, Chen H, Zhao L, Li C, et al. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med. 2018;10:eaap9840.PubMedCrossRef

20.

Shen T, Lu Y, Zhang Q. High squalene epoxidase in tumors predicts worse survival in patients with hepatocellular carcinoma: integrated bioinformatic analysis on NAFLD and HCC. Cancer Control. 2020;27:107327482091466.CrossRef

21.

Zhao K, Zhao Y, Zhu J, Dong H, Cong W, Yu Y, et al. A panel of genes identified as targets for 8q24.13–24.3 gain contributing to unfavorable overall survival in patients with hepatocellular carcinoma. Curr Med Sci. 2018;38:590–6.PubMedCrossRef

22.

Sun H, Li L, Li W, Yang F, Zhang Z, Liu Z, et al. p53 transcriptionally regulates SQLE to repress cholesterol synthesis and tumor growth. EMBO Rep. 2021;22:525–37.CrossRef

23.

Zhang Z, Wu W, Jiao H, Chen Y, Ji X, Cao J, et al. Squalene epoxidase promotes hepatocellular carcinoma development by activating STRAP transcription and TGF-β/SMAD signalling. Br J Pharmacol. 2023;180:1562–81.PubMedCrossRef

24.

Moon S-H, Huang C-H, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP, et al. p53 represses the mevalonate pathway to mediate tumor suppression. Cell. 2019;176:564–80.PubMedCrossRef

25.

Che L, Chi W, Qiao Y, Zhang J, Song X, Liu Y, et al. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut. 2020;69:177–86.PubMedCrossRef

26.

Zhang F, Gao J, Liu X, Sun Y, Liu L, Hu B, et al. LATS-regulated nuclear-cytoplasmic translocation of SREBP2 inhibits hepatocellular carcinoma cell migration and invasion via Epithelial–mesenchymal transition. Mol Carcinog. 2023;62:963–74.PubMedCrossRef

27.

Wei M, Nurjanah U, Herkilini A, Huang C, Li Y, Miyagishi M, et al. Unspliced XBP1 contributes to cholesterol biosynthesis and tumorigenesis by stabilizing SREBP2 in hepatocellular carcinoma. Cell Mol Life Sci. 2022;79:472.PubMedCrossRef

28.

Chen K-J, Jin R-M, Shi C-C, Ge R-L, Hu L, Zou Q-F, et al. The prognostic value of Niemann-Pick C1-like protein 1 and Niemann-Pick disease type C2 in hepatocellular carcinoma. J Cancer. 2018;9:556–63.PubMedPubMedCentralCrossRef

29.

Barretto N, Sainz B, Hussain S, Uprichard SL. Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread. J Virol. 2014;88:5050–61.PubMedPubMedCentralCrossRef

30.

Zhang Z, Qin S, Chen Y, Zhou L, Yang M, Tang Y, et al. Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy. EMBO Mol Med. 2022;14: e14903.PubMedPubMedCentralCrossRef

31.

Criscuolo D, Avolio R, Calice G, Laezza C, Paladino S, Navarra G, et al. Cholesterol homeostasis modulates platinum sensitivity in human ovarian cancer. Cells. 2020;9:828.PubMedPubMedCentralCrossRef

32.

Zhang G-M, Chen W, Yao Y, Luo L, Sun L-J. LDLR promotes growth and invasion in renal cell carcinoma and activates the EGFR pathway. Neoplasma. 2022;69:113–22.PubMedCrossRef

33.

Zeng J, Wu Y, Liao Q, Li L, Chen X, Chen X. Liver X receptors agonists impede hepatitis C virus infection in an Idol-dependent manner. Antiviral Res. 2012;95:245–56.PubMedCrossRef

34.

Zhao L-J, Wang L, Ren H, Cao J, Li L, Ke J-S, et al. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. Exp Cell Res. 2005;305:23–32.PubMedCrossRef

35.

Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, et al. Decreased PCSK9 expression in human hepatocellular carcinoma. BMC Gastroenterol. 2015;15:176.PubMedPubMedCentralCrossRef

36.

Chen Z, Chen L, Sun B, Liu D, He Y, Qi L, et al. LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway. Mol Metab. 2021;51: 101230.PubMedPubMedCentralCrossRef

37.

Shen S, Wang R, Qiu H, Li C, Wang J, Xue J, et al. Development of an autophagy-based and stemness-correlated prognostic model for hepatocellular carcinoma using bulk and single-cell RNA-sequencing. Front Cell Dev Biol. 2021;9: 743910.PubMedPubMedCentralCrossRef

38.

Wang G, Guan J, Yang Q, Wu F, Shao J, Zhou Q, et al. Development of a bile acid-related gene signature for predicting survival in patients with hepatocellular carcinoma. Comput Math Methods Med. 2022;2022:1–14.

39.

Du X, Zhang Y, Jo SR, Liu X, Qi Y, Osborne B, et al. Akt activation increases cellular cholesterol by promoting the proteasomal degradation of Niemann-Pick C1. Biochem J. 2015;471:243–53.PubMedCrossRef

40.

Liao Y-J, Fang C-C, Yen C-H, Hsu S-M, Wang C-K, Huang S-F, et al. Niemann-Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: clinicopathological correlations and therapeutical implications—identification of antitumoral protein NPC2 in liver cancer. Int J Cancer. 2015;137:1341–51.PubMedCrossRef

41.

Suk F-M, Wang Y-H, Chiu W-C, Liu C-F, Wu C-Y, Chen T-L, et al. Secretory NPC2 protein-mediated free cholesterol levels were correlated with the sorafenib response in hepatocellular carcinoma. IJMS. 2021;22:8567.PubMedPubMedCentralCrossRef

42.

Liao Y-J, Chen T-L, Lee T-S, Wang H-A, Wang C-K, Liao L-Y, et al. Glycine N-methyltransferase deficiency affects Niemann-Pick type C2 protein stability and regulates hepatic cholesterol homeostasis. Mol Med. 2012;18:412–22.PubMedCrossRef

43.

Fu B, Meng W, Zhao H, Zhang B, Tang H, Zou Y, et al. GRAM domain-containing protein 1A (GRAMD1A) promotes the expansion of hepatocellular carcinoma stem cell and hepatocellular carcinoma growth through STAT5. Sci Rep. 2016;6:31963.PubMedPubMedCentralCrossRef

44.

Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 1995;9:1033–45.PubMedCrossRef

45.

Na T-Y, Shin YK, Roh KJ, Kang S-A, Hong I, Oh SJ, et al. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2009;49:1122–31.PubMedCrossRef

46.

Kim K, Kim KH, Kim HH, Cheong J. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. Biochem J. 2008;416:219–30.PubMedCrossRef

47.

García-Mediavilla MV, Pisonero-Vaquero S, Lima-Cabello E, Benedicto I, Majano PL, Jorquera F, et al. Liver X receptor α-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication. Lab Invest. 2012;92:1191–202.PubMedCrossRef

48.

Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y, Abe T, et al. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci USA. 2007;104:1661–6.PubMedPubMedCentralCrossRef

49.

Bakiri L, Hamacher R, Graña O, Guío-Carrión A, Campos-Olivas R, Martinez L, et al. Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation. J Exp Med. 2017;214:1387–409.PubMedPubMedCentralCrossRef

50.

Hu C, Liu D, Zhang Y, Lou G, Huang G, Chen B, et al. LXRα-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells. Oncogene. 2014;33:2888–97.PubMedCrossRef

51.

He J, Yang T, He W, Jiang S, Zhong D, Xu Z, et al. Liver X receptor inhibits the growth of hepatocellular carcinoma cells via regulating HULC/miR-134-5p/FOXM1 axis. Cell Signal. 2020;74: 109720.PubMedCrossRef

52.

Xiong H, Zhang Y, Chen S, Ni Z, He J, Li X, et al. Induction of SOCS3 by liver X receptor suppresses the proliferation of hepatocellular carcinoma cells. Oncotarget. 2017;8:64083–94.PubMedPubMedCentralCrossRef

53.

Bellomo C, Caja L, Fabregat I, Mikulits W, Kardassis D, Heldin C-H, et al. Snail mediates crosstalk between TGFβ and LXRα in hepatocellular carcinoma. Cell Death Differ. 2018;25:885–903.PubMed

54.

Morén A, Bellomo C, Tsubakihara Y, Kardassis D, Mikulits W, Heldin C-H, et al. LXRα limits TGFβ-dependent hepatocellular carcinoma associated fibroblast differentiation. Oncogenesis. 2019;8:36.PubMedPubMedCentralCrossRef

55.

Lin Z, Xia S, Liang Y, Ji L, Pan Y, Jiang S, et al. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription. Theranostics. 2020;10:8834–50.PubMedPubMedCentralCrossRef

56.

Rudalska R, Harbig J, Snaebjornsson MT, Klotz S, Zwirner S, Taranets L, et al. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat Cancer. 2021;2:201–17.PubMedCrossRef

57.

Long H, Guo X, Qiao S, Huang Q. Tumor LXR expression is a prognostic marker for patients with hepatocellular carcinoma. Pathol Oncol Res. 2018;24:339–44.PubMedCrossRef

58.

Li Z, Wang Y, Xing R, Zeng H, Yu X-J, Zhang Y-J, et al. Cholesterol efflux drives the generation of immunosuppressive macrophages to promote the progression of human hepatocellular carcinoma. Cancer Immunol Res. 2023;11:1400–13.PubMedCrossRef

59.

Hou H, Kang Y, Li Y, Zeng Y, Ding G, Shang J. miR-33a expression sensitizes Lgr5+ HCC-CSCs to doxorubicin via ABCA1. Neo. 2017;64:81–91.CrossRef

60.

Xi B, Luo F-Z, He B, Wang F, Li Z-K, Lai M-C, et al. High nuclear ABCG1 expression is a poor predictor for hepatocellular carcinoma patient survival. Hepatobiliary Pancreat Dis Int. 2022;21:370–7.PubMedCrossRef

61.

Liao X, Song G, Xu Z, Bu Y, Chang F, Jia F, et al. Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma. BMC Cancer. 2020;20:31.PubMedPubMedCentralCrossRef

62.

Liao X, Zhang Y, Xu B, Ali A, Liu X, Jia Q. Inositol hexaphosphate sensitizes hepatocellular carcinoma to oxaliplatin relating inhibition of CCN2-LRP6-β-catenin-ABCG1 signaling pathway. J Cancer. 2021;12:6071–80.PubMedPubMedCentralCrossRef

63.

Zhao Z, Zhao Z, Wang J, Zhang H, Xi Z, Xia Q. ABCC6 knockdown fuels cell proliferation by regulating PPARα in hepatocellular carcinoma. Front Oncol. 2022;12: 840287.PubMedPubMedCentralCrossRef

64.

Cui Y, Liang S, Zhang S, Zhang C, Zhao Y, Wu D, et al. ABCA8 is regulated by miR-374b-5p and inhibits proliferation and metastasis of hepatocellular carcinoma through the ERK/ZEB1 pathway. J Exp Clin Cancer Res. 2020;39:90.PubMedPubMedCentralCrossRef

65.

Kinslechner K, Schörghofer D, Schütz B, Vallianou M, Wingelhofer B, Mikulits W, et al. Malignant phenotypes in metastatic melanoma are governed by SR-BI and its association with glycosylation and STAT5 activation. Mol Cancer Res. 2018;16:135–46.PubMedCrossRef

66.

Feng H, Wang M, Wu C, Yu J, Wang D, Ma J, et al. High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in lung adenocarcinoma: a STROBE compliant article. Medicine. 2018;97: e0203.PubMedPubMedCentralCrossRef

67.

Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol. 2010;84:34–43.PubMedCrossRef

68.

Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY, et al. Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1–mediated lipogenesis. Clin Cancer Res. 2016;22:5337–48.PubMedPubMedCentralCrossRef

69.

Li J, Gu D, Lee SS-Y, Song B, Bandyopadhyay S, Chen S, et al. Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene. 2016;35:6378–88.PubMedPubMedCentralCrossRef

70.

Yue S, Li J, Lee S-Y, Lee HJ, Shao T, Song B, et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 2014;19:393–406.PubMedPubMedCentralCrossRef

71.

Khatib SA, Wang XW. Proteomic heterogeneity reveals SOAT1 as a potential biomarker for hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2019;4:37.PubMedPubMedCentralCrossRef

72.

Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567:257–61.PubMedCrossRef

73.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.PubMedCrossRef

74.

Wang Z, Wang M, Zhang M, Xu K, Zhang X, Xie Y, et al. High-affinity SOAT1 ligands remodeled cholesterol metabolism program to inhibit tumor growth. BMC Med. 2022;20:292.PubMedPubMedCentralCrossRef

75.

Zhu Y, Gu L, Lin X, Zhou X, Lu B, Liu C, et al. P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis. Hepatology. 2023;77:1499–511.PubMedCrossRef

76.

Chen Y, Yang X, Chen Y, Chen G, Winkler CA, An P, et al. Impacts of the SOAT1 genetic variants and protein expression on HBV-related hepatocellular carcinoma. BMC Cancer. 2021;21:615.PubMedPubMedCentralCrossRef

77.

Lu M, Hu X-H, Li Q, Xiong Y, Hu G-J, Xu J-J, et al. A specific cholesterol metabolic pathway is established in a subset of HCCs for tumor growth. J Mol Cell Biol. 2013;5:404–15.PubMedPubMedCentralCrossRef

78.

Zhang X, Coker OO, Chu ES, Fu K, Lau HCH, Wang Y-X, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70:761–74.PubMedCrossRef

79.

Kim M-H, Kim M-Y, Salloum S, Qian T, Wong LP, Xu M, et al. Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature. Hepatol Commun. 2022;6:2581–93.PubMedPubMedCentralCrossRef

80.

Ghalali A, Martin-Renedo J, Högberg J, Stenius U. Atorvastatin decreases HBx-induced phospho-Akt in hepatocytes via P2X receptors. Mol Cancer Res. 2017;15:714–22.PubMedCrossRef

81.

Wang S-T, Huang S-W, Liu K-T, Lee T-Y, Shieh J-J, Wu C-Y. Atorvastatin-induced senescence of hepatocellular carcinoma is mediated by downregulation of hTERT through the suppression of the IL-6/STAT3 pathway. Cell Death Discov. 2020;6:17.PubMedPubMedCentralCrossRef

82.

Deza Z, Caimi GR, Noelia M, Coli L, Ridruejo E, Alvarez L. Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF-β1/pERK signaling pathway. Mol Carcinog. 2023;62:398–407.PubMedCrossRef

83.

Yang P-M, Liu Y-L, Lin Y-C, Shun C-T, Wu M-S, Chen C-C. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 2010;70:7699–709.PubMedCrossRef

84.

Relja B, Meder F, Wilhelm K, Henrich D, Marzi I, Lehnert M. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010;26:735–41.PubMedCrossRef

85.

Wang S-T, Ho HJ, Lin J-T, Shieh J-J, Wu C-Y. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis. 2017;8: e2626.PubMedPubMedCentralCrossRef

86.

Elleithi YA, El-Gayar AM, Amin MN. Simvastatin induces apoptosis and suppresses hepatocellular carcinoma induced in rats. Appl Biochem Biotechnol. 2023;195:1656–74.PubMedCrossRef

87.

Huang X, Ma J, Xu J, Su Q, Zhao J. Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression. Mol Med Rep. 2015;11:2334–40.PubMedCrossRef

88.

Feng J, Dai W, Mao Y, Wu L, Li J, Chen K, et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis. J Exp Clin Cancer Res. 2020;39:24.PubMedPubMedCentralCrossRef

89.

Horie M, Tsuchiya Y, Hayashi M, Iida Y, Iwasawa Y, Nagata Y, et al. NB-598: a potent competitive inhibitor of squalene epoxidase. J Biol Chem. 1990;265:18075–8.PubMedCrossRef

90.

Yin F, Feng F, Wang L, Wang X, Li Z, Cao Y. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. Cell Death Dis. 2019;10:672.PubMedPubMedCentralCrossRef

91.

Fan M, Chen Z, Shao W, Chen Y, Lin Z, Yi C, et al. SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway. Acta Biochim Biophys Sin (Shanghai). 2023. https://doi.org/10.3724/abbs.2023122.CrossRefPubMed

92.

Ren M, Xu H, Xia H, Tang Q, Bi F. Simultaneously targeting SOAT1 and CPT1A ameliorates hepatocellular carcinoma by disrupting lipid homeostasis. Cell Death Discov. 2021;7:125.PubMedPubMedCentralCrossRef

93.

Hu L, Li J, Cai H, Yao W, Xiao J, Li Y-P, et al. Avasimibe: a novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles. Antiviral Res. 2017;148:5–14.PubMedCrossRef

94.

Ma S, Lv M, Chen X, Zang G, Tang Z, Zhang Y, et al. Avasimibe can cooperate with a DC-targeting and integration-deficient lentivector to induce stronger HBV specific T cytotoxic response by regulating cholesterol metabolism. Antiviral Res. 2023;216: 105662.PubMedCrossRef

95.

Yang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature. 2016;531:651–5.PubMedPubMedCentralCrossRef

96.

Zhao L, Li J, Liu Y, Kang L, Chen H, Jin Y, et al. Cholesterol esterification enzyme inhibition enhances antitumor effects of human chimeric antigen receptors modified T cells. J Immunother. 2018;41:45–52.PubMedCrossRef

97.

Pal P, Gandhi H, Giridhar R, Yadav MR. ACAT inhibitors: the search for novel cholesterol lowering agents. Mini Rev Med Chem. 2013;13:1195–219.PubMedCrossRef

98.

He X, Zhu M, Zheng J, Wang C, Zhao X, Zhang B, et al. Liver X receptor agonists exert antitumor effects against hepatocellular carcinoma via inducing REPS2 expression. Acta Pharmacol Sin. 2022;44:635–46.PubMedCrossRef

99.

Shao W, Zhu W, Lin J, Luo M, Lin Z, Lu L, et al. Liver X receptor agonism sensitizes a subset of hepatocellular carcinoma to sorafenib by dual-inhibiting MET and EGFR. Neoplasia. 2020;22:1–9.PubMedCrossRef

100.

Shiragannavar VD, Gowda NGS, Kumar DP, Mirshahi F, Santhekadur PK. Withaferin A acts as a novel regulator of liver X receptor-α in HCC. Front Oncol. 2020;10: 628506.PubMedCrossRef

101.

Shiragannavar VD, Gowda NGS, Santhekadur PK. Discovery of eukaryotic cellular receptor for Withaferin A, a multifaceted drug from Withania somnifera plant. Med Drug Discov. 2022;14: 100127.CrossRef

102.

Zhang Y, Tan Y, Liu S, Yin H, Duan J, Fan L, et al. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis. Toxicol Mech Methods. 2023;33:47–55.PubMedCrossRef

Title: Dysregulated cholesterol regulatory genes in hepatocellular carcinoma
Authors: Dan Cao
Huan Liu
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01547-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dysregulated cholesterol regulatory genes in hepatocellular carcinoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Arthroscopic Bankart repair versus conservative treatment for first-time traumatic anterior shoulder dislocation: a systematic review and meta-analysis

Contrast media extravasation injury: a prospective observational cohort study

Acute subdural haematoma exacerbates cerebral blood flow disorder and promotes the development of intraoperative brain bulge in patients with severe traumatic brain injury

Both extracellular vesicles from helicobacter pylori-infected cells and helicobacter pylori outer membrane vesicles are involved in gastric/extragastric diseases

The efficacy of traditional Chinese medicine in the treatment of the COVID-19 pandemic in Henan Province: a retrospective study

m1A Regulatory gene signatures are associated with certain immune cell compositions of the tumor microenvironment and predict survival in kidney renal clear cell carcinoma